Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

58.82USD
22 Jul 2016
Change (% chg)

$0.03 (+0.05%)
Prev Close
$58.79
Open
$59.01
Day's High
$59.08
Day's Low
$58.56
Volume
2,086,422
Avg. Vol
2,802,049
52-wk High
$60.06
52-wk Low
$45.70

Select another date:

Fri, Jul 22 2016

BRIEF-Merck says EMA has accepted file for formulation of Isentress for review

* Says European Medicines Agency (EMA) has accepted file for investigational once-daily formulation of isentress for review

Ruling invalidating Merck patent over on-sale bar stayed

U.S. Supreme Court Chief Justice John Roberts issued a stay on Thursday of an appeals court decision that would allow Actavis PLC to launch generic versions of Bayer AG's birth control drugs Safyral and Beyaz in response to an application from Bayer and Merck & Co.

BRIEF-Merck provides regulatory update on Biologics application

* Fda has requested submission of new data and analyses from modify I and modify II clinical trials previously submitted

UK charity pockets $150 million from Merck cancer immunotherapy drug

LONDON British medical charity MRC Technology has pocketed $150 million by selling part of its royalty interest in Merck & Co's successful cancer drug Keytruda, allowing it to plough fresh funds into new research.

UK charity pockets $150 mln from Merck cancer immunotherapy drug

LONDON, July 15 British medical charity MRC Technology has pocketed $150 million by selling part of its royalty interest in Merck & Co's successful cancer drug Keytruda, allowing it to plough fresh funds into new research.

BRIEF- Merck's Healthcare invests majority stake in Staywell

* Merck's Healthcare Services & Solutions invests in majority stake in Staywell

REFILE-BRIEF-Pfizer and Germany's Merck KGaA initiate phase III trial

* Merck KGaA and Pfizer initiate phase III trial to evaluate avelumab as first-line treatment for ovarian cancer

Merck appeals order reversing its $200 mln verdict against Gilead

Merck & Co has appealed a California federal judge's order that overturned a $200 million verdict it won in a patent case against Gilead Sciences over Gilead's lucrative hepatitis C drugs on the grounds that Merck engaged in extensive misconduct.

BRIEF-Merck Animal Health to buy controlling interest in Vallée S.A

* Will acquire approximately 93 pct of shares of Vallée S.A. at closing, in exchange for a payment of $400 mln

BRIEF-Merck, Premier Inc collaborate to improve care for osteoporosis patients

* Merck And Premier Inc collaborate to prevent fractures for osteoporosis patients

Select another date: